Target Name: ELAC1
NCBI ID: G55520
Review Report on ELAC1 Target / Biomarker Content of Review Report on ELAC1 Target / Biomarker
ELAC1
Other Name(s): deleted in Ma29 | tRNase Z 1 | RNase Z 1 | ElaC homolog protein 1 | D29 | tRNA Z (short form) | zinc phosphodiesterase ELAC protein 1 | Zinc phosphodiesterase ELAC protein 1 | RNaseZ(S) | tRNase ZS |

ELAC1: A Potential Drug Target and Biomarker

ELAC1 (endoplasmic reticulum-associated protein 1) is a protein that is expressed in various cell types, including neurons, muscle cells, and blood vessels. It is involved in the regulation of protein trafficking from the endoplasmic reticulum (ER) to the cytoplasm, which is the fluid that surrounds the cells. ELAC1 has been shown to play a role in a variety of physiological processes, including cell signaling, protein folding, and intracellular trafficking.

Recent studies have suggested that ELAC1 may also have potential as a drug target or biomarker. In this article, we will explore the potential of ELAC1 as a drug target and biomarker, as well as its potential clinical applications.

Potential Drug Target

ELAC1 has been shown to interact with several protein targets, including the protein tyrosine kinase (TK) and the protein serine/threonine kinase (STK). TK and STK are involved in cell signaling and are potential drug targets for a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

ELAC1 has been shown to regulate the activity of TK and STK, which are involved in the regulation of protein function and cell signaling. By targeting these protein targets, ELAC1 may be a potential drug for a variety of diseases. For example, TK-deficient mice have been shown to have increased sensitivity to drugs that inhibit TK activity, suggesting that ELAC1 may be a useful target for cancer therapies.

In addition to its potential as a drug target, ELAC1 has also been shown to be a potential biomarker for a variety of diseases. The regulation of protein trafficking by ELAC1 has been implicated in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

Potential Biomarker

ELAC1 has been shown to be involved in the regulation of protein trafficking from the ER to the cytoplasm, which is the fluid that surrounds the cells. This regulation is critical for the function of many cellular processes, including the delivery of proteins to the cytoplasm and the removal of proteins from the ER.

ELAC1 has been shown to play a role in the regulation of protein trafficking by interacting with the protein tyrosine kinase (TK) and the protein serine/threonine kinase (STK). These proteins are involved in the regulation of protein function and cell signaling, and have been implicated in the development and progression of a variety of diseases.

In addition to its potential as a biomarker, ELAC1 has also been shown to be involved in the regulation of cellular processes that are implicated in the development and progression of many diseases. For example, ELAC1 has been shown to be involved in the regulation of the clearance of damaged proteins from the ER, which is thought to play a role in the development of neurodegenerative diseases.

Clinical Applications

ELAC1 has been shown to have potential as a drug target and biomarker, and its clinical applications are still being explored. One potential application of ELAC1 as a drug target is the treatment of diseases that are characterized by the accumulation of damaged or misfolded proteins in the cells, such as neurodegenerative diseases and cancer.

For example, ELAC1 has been shown to be involved in the regulation of the clearance of damaged proteins from the ER, which is thought to play a role in the development of neurodegenerative diseases. Therefore, inhibiting ELAC1 activity

Protein Name: ElaC Ribonuclease Z 1

Functions: Zinc phosphodiesterase, which displays some tRNA 3'-processing endonuclease activity. Probably involved in tRNA maturation, by removing a 3'-trailer from precursor tRNA

The "ELAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS